NCT01637142

A Study of LY2140023 in Healthy Participants

An Absolute Bioavailability Study of LY2140023 and LY404039 in Healthy Subjects Using the Intravenous Tracer Method

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Denovo Biopharma LLC · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the extent and rate of absorption of LY2140023 in healthy participants. The study has two periods. In Treatment Period 1, participants will receive a single oral dose of 80 milligrams (mg) LY2140023 followed by a 2-hour intravenous (IV) infusion of approximately 100 micrograms (µg) LY2140023 containing approximately 100 nanocuries (nCi) \[14C\]-LY2140023. In Treatment Period 2, participants will receive an oral dose of 80 mg LY2140023 followed by a 2-hour IV infusion of approximately 100 µg LY404039 containing approximately 100 nCi \[14C\]-LY404039. There will be at least a 3-day washout between doses.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	LY2140023	Administered orally.
DRUG	14C-LY2140023	Administered IV.
DRUG	14C-LY404039	Administered IV.

Timeline

• Start date: 2012-07-01
• Primary completion: 2012-07-01
• Completion: 2012-07-01
• First posted: 2012-07-11
• Last updated: 2021-09-21
• Results posted: 2021-09-21

Locations

1 site across 1 country: United Kingdom